Molecular Medicine

, Volume 13, Issue 9–10, pp 518–526 | Cite as

Selective Suppression of NF-kBp65 in Hepatitis Virus-Infected Pregnant Women Manifesting Severe Liver Damage and High Mortality

  • Bhupesh K. Prusty
  • Suresh Hedau
  • Ajay Singh
  • Premasis Kar
  • Bhudev C. Das
Research Article


Fulminant hepatitis in Asian pregnant women is generally caused by hepatitis E virus infection, and extremely high mortality is most common in them. Decreased cell-mediated immunity is considered a major cause of death in these cases, but what exactly influences decreased immunity and high mortality specifically during pregnancy is not known. We used electrophoretic mobility shift assays, immunoblotting, and immunohistochemical analysis to study the expression and DNA binding activity of NF-kB p50 and NF-kB p65 in pregnant fulminant hepatic failure (FHF) patients and compared them with their nonpregnant counterparts. In both PBMC and postmortem liver biopsy specimens the DNA-binding activity of NF-kB was very high in samples from pregnant FHF patients compared with those from nonpregnant women as well as pregnant women with acute viral hepatitis (AVH) without FHF. Further dissection of the NF-kB complex in supershift assays demonstrated complete absence of p65 in the NF-kB complex, which is formed by homodimerization of the p50 component in pregnant FHF patients. Western blotting and immunohistochemical analysis of the expression of p50 and p65 proteins both showed higher levels of p50 expression and a complete absence or a minimal expression of p65, indicating its nonparticipation in NF-kB-dependent transactivation in pregnant FHF patients. We suggest that the exclusion of p65 from the NF-kB transactivation complex seems to be a crucial step that may cause deregulated immunity and severe liver damage, leading to the death of the patient. Our findings provide a molecular basis, for developing novel therapeutic approaches.



The study was funded by Indian Council of Medical Research and Department of Biotechnology, Government of India, New Delhi. BKP received SRF funding from the Council of Scientific and Industrial Research, Government of India. Authors thank Dr. Alok C. Bharti for critical discussion.


  1. 1.
    Khuroo MS, Teli MR, Skidmore S, Sofi MA, Khuroo MI. (1981) Incidence and severity of viral hepatitis in pregnancy. Am. J. Med. 70:252–5.CrossRefGoogle Scholar
  2. 2.
    Balayan MS. (1997) Epidemiology of Hepatitis E virus infection. J. Viral Hepatitis 4:155–65.CrossRefGoogle Scholar
  3. 3.
    Dilawari JB, Singh K, Chawla YK, et al. (1994) Hepatitis E virus, epidemiological, clinical and serological studies of a north Indian epidemic. Indian J. Gastroenterol. 134:44–8.Google Scholar
  4. 4.
    Arankalle VA, Chobe LP, Jha J, et al. (1993) Aetiology of acute sporadic non-A, non-B viral hepatitis in India. J. Med. Virol. 40:121–5.CrossRefGoogle Scholar
  5. 5.
    Tsega E, Krawczynski K, Hansson BG, Nordenfelt E. (1993) Hepatitis E virus infection in pregnancy in Ethiopia. Ethiop. Med. J. 31:173–81.PubMedGoogle Scholar
  6. 6.
    Cahill KM. (1962) Hepatitis in pregnancy. Surg. Gynecol. Obstet. 11:545–52.Google Scholar
  7. 7.
    Purdy MA, Krawczynski K. (1994) Hepatitis E. Gastroenterol. Clin. North Am. 23:537–46.PubMedGoogle Scholar
  8. 8.
    Hamid SS, Jafri SM, Khan H, Shah H, Abbas Z, Fields H. (1996) Fulminant hepatic failure in 526 pregnant women: acute fatty liver or acute viral hepatitis? J. Hepato. 25:20–7.CrossRefGoogle Scholar
  9. 9.
    Arankalle VA, Chadha MS, Dama BM, Tsarey SA, Purcell RH, Banerjee K. (1998) Role of immune serum globulins in pregnant women during an epidemic of hepatitis E. J. Viral Hepat. 5:199–204.CrossRefGoogle Scholar
  10. 10.
    Siebenlist U, Franzoso G, Brown K. (1994) Structure, regulation and function of NF-kappa B. Ann. Rev. Cell Biol. 10:405–55.CrossRefGoogle Scholar
  11. 11.
    Ghosh S, May MJ, Kopp EB. (1998) NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Ann. Rev. Immunol. 16:225–60.CrossRefGoogle Scholar
  12. 12.
    Baeuerle PA, Baltimore D. (1998) Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor. Cell 53:211–7.CrossRefGoogle Scholar
  13. 13.
    Baeuerle PA, Baltimore D. (1998) I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 242:540–6.CrossRefGoogle Scholar
  14. 14.
    Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. (1995) Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 376:167–70.CrossRefGoogle Scholar
  15. 15.
    Trey C, Davidson C. (1970) The management of fulminant hepatic failure. Prog. Liver Dis. 3: 282–98.PubMedGoogle Scholar
  16. 16.
    Madan K, Gopalkrishna V, Kar P, Sharma JK, Das UP, Das BC. (1998) Detection of hepatitis C and E virus genome in sera of patients with acute viral hepatitis and fulminant hepatitis by their simultaneous amplification in PCR. J. Gastroenterol. Hepatol. 13:125–30.CrossRefGoogle Scholar
  17. 17.
    Goldsmith R, Yarbough PO, Reyes GR, et al. (1992) Enzyme-linked immunosorbent assay for diagnosis of acute sporadic hepatitis E in Egyptian children. Lancet 339:328–31.CrossRefGoogle Scholar
  18. 18.
    Katiyar S, Dash BC, Thakur V, Guptan RC, Sarin SK, Das BC. (2000) p53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India. Cancer 88:1565–73.CrossRefGoogle Scholar
  19. 19.
    Prusty BK, Das BC. (2005) Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP-1 activity in HeLa cells by curcumin. Int. J. Cancer 113: 951–60.CrossRefGoogle Scholar
  20. 20.
    Sambrook J, Russel, DW. (2001) Molecular cloning: a laboratory manual. 3rd ed. New York: Cold Spring Harbor Laboratory Press; p. 957–9.Google Scholar
  21. 21.
    McCracken SA, Drury CL, Lee HS, Morris JM. (2003) Pregnancy is associated with suppression of the nuclear factor kappaB/IkappaB activation pathway in peripheral blood mononuclear cells. J. Reprod. Immunol. 58:27–47.CrossRefGoogle Scholar
  22. 22.
    Boya P, Larrea E, Sola I, Majano PL, Jiménez C, Civeira MP, Prieto J. (2001) Nuclear factor-kappa B in the liver of patients with chronic hepatitis C: decreased RelA expression is associated with enhanced fibrosis progression. Hepatology 34: 1041–8.CrossRefGoogle Scholar
  23. 23.
    La Rosa FA, Pierce JW, Sonenshein GE. (1994) Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel family of transcription factors. Mol. Cell Biol. 14:1039–44.CrossRefGoogle Scholar
  24. 24.
    Wu H, Lozano G. (1994) NF-kappa B activation of p53. A potential mechanism for suppressing cell growth in response to stress. J. Biol. Chem. 269:20067–74.PubMedGoogle Scholar
  25. 25.
    McCracken SA, Gallery E, Morris JM. (2004) Pregnancy-specific down-regulation of NF-kappa B expression in T cells in humans is essential for the maintenance of the cytokine profile required for pregnancy success. J. Immunol. 172:4583–91.CrossRefGoogle Scholar
  26. 26.
    Purtilo DT, Hallgren HM, Yunis EJ. (1972) Depressed maternal lymphocyte response to phytohaemaglutinin in human pregnancy. Lancet 1: 769–71.CrossRefGoogle Scholar
  27. 27.
    Lewis J Jr, Whang J, Negal B, Oppenheim JJ, Perry S. (1966) Lymphocyte transformation in mixed leukocyte cultures in women with normal pregnancy or, tumors of placental origin. A preliminary report. Am. J. Obstet. Gynecol. 96:287–90.CrossRefGoogle Scholar
  28. 28.
    Hsia DY, Taylor RG, Gellis SS. (1952) Long-term follow-up study of infectious hepatitis in pregnancy. J. Pediatr. 41:13–17.CrossRefGoogle Scholar
  29. 29.
    Jilani N, Das BC, Husain SA, et al. (2005) Hepatitis E virus infection and fulminant hepatic failure (FHF) during pregnancy. J. Gastroenterol. Hepatol. 22:676–82.CrossRefGoogle Scholar
  30. 30.
    Liao QL, Ye LB, Timani KA, et al. (2005) Hepatitis C virus non-structural 5A protein can enhance full-length core protein-induced nuclear factor-kappa B activation. World J. Gastroenterol. 11: 6433–9.CrossRefGoogle Scholar
  31. 31.
    Hassan M, Selimovic D, Ghozlan H, et al. (2007) Induction of high-molecular-weight (HMW) tumor necrosis factor (TNF) alpha by hepatitis C virus (HCV) non-structural protein 3 (NS3) in liver cells is AP-1 and NF-kappa B-dependent activation. Cell Signal. 19:301–11.CrossRefGoogle Scholar
  32. 32.
    Kanda T, Yokosuka O, Nagao K, Saisho H. (2006) State of hepatitis C viral replication enhances activation of NF-kB- and AP-1-signaling induced by hepatitis B virus X. Cancer Lett. 234:143–8.CrossRefGoogle Scholar
  33. 33.
    Muto Y, Nouri-Aria KT, Meager A, Alexander GJ, Eddleston AL, Williams R. (1988) Enhanced tumor necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 2:72–4.CrossRefGoogle Scholar
  34. 34.
    de la Mata M, Meager A, Ralando N, Daniels HM, Nouri-Aria KT, Goka AK. (1990) Tumor necrosis factor production in fulminant hepatic failure: relation to etiology and superimposed microbial infection. Clin. Exp. Immunol. 82:479–84.CrossRefGoogle Scholar
  35. 35.
    Andus T, Bauer J, Gerok W. (1991) Effects of cytokines on the liver. Hepatology 13:364–75.CrossRefGoogle Scholar
  36. 36.
    Mellor AM, Munn DH. (1999) Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol. Today 20:469–73.CrossRefGoogle Scholar
  37. 37.
    Vancurova I, Wu R, Miskolci V, Sun S. (2002) Increased p50/p50 NF-kappa B activation in human papillomavirus type 6- or type 11-induced laryngeal papilloma tissue. J. Virol. 76:1533–6.CrossRefGoogle Scholar
  38. 38.
    Prusty BK, Husain SA, Das BC. (2005) Constitutive activation of nuclear factor-kB: preferential homodimerization of p50 subunits in cervical carcinoma. Front. Biosci. 10:1510–9.CrossRefGoogle Scholar
  39. 39.
    Mishra A, Bharti AC, Varghese P, Saluja D, Das BC. (2006) Differential expression and activation of NF-kappa B family proteins during oral carcinogenesis: Role of high risk human papillomavirus infection. Int. J. Cancer 119:2840–50.CrossRefGoogle Scholar
  40. 40.
    Ponta H, Kennedy N, Scroch P, Hynes NE, Groner B. (1985) The hormonal response region in the mouse mammary tumor virus long terminal repeat can be dissociated from the proviral promoter and has enhancer properties. Proc. Natl. Acad. Sci. USA. 1020–4.Google Scholar
  41. 41.
    Gopalkrishna V, Murthy NS, Sharma JK, et al. (1995) Increased human papillomavirus infection with increasing number of pregnancies in Indian women. J. Infect. Dis. 171:254–5.CrossRefGoogle Scholar
  42. 42.
    Karpa R, Laub O. (1990) Corticosteroids stimulate hepatitis B virus DNA, mRNA and protein production in a stable expression system. Hepatol. 11:34–6.CrossRefGoogle Scholar
  43. 43.
    Piyathilake CJ, Henao OL, Macaluso M, et al. (2004) Folate is associated with the natural history of high-risk human papillomaviruses. Cancer Res. 64:8788–93.CrossRefGoogle Scholar
  44. 44.
    Dhur A, Galan P, Hercberg S. (1991) Folate status and the immune system. Prog. Food Nutr. Sci. 15: 43–60.PubMedGoogle Scholar
  45. 45.
    Jukes TH. (1983) Folic acid deficiency. Nature 301: 192.CrossRefGoogle Scholar
  46. 46.
    Mukherjee M, Joshi S, Bagadi S, Dalvi M, Rao A, Shetty KR. (2002) Alow prevalence of the C677T mutation in the methylenetetrahydrofolate reductase gene in Asian Indians. Clin. Genet. 61: 155–59.CrossRefGoogle Scholar
  47. 47.
    Radha Rama Devi A, Govindaiah V, Ramakrishna G. (2004) Prevalence of methylene tetrahydrofolate reductase polymorphism in south Indian population. Curr. Sci. 86:440–43.Google Scholar
  48. 48.
    Hohler T, Reuss E, Evers N, et al. (2002) Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet 360:991–95.CrossRefGoogle Scholar
  49. 49.
    Thio CL, Carrington M, Marti D, et al. (1999) Class II HLA alleles and hepatitis B virus persistence in African Americans. J. Infect. Dis. 179:1004–6.CrossRefGoogle Scholar

Copyright information

© Feinstein Institute for Medical Research 2007

Authors and Affiliations

  • Bhupesh K. Prusty
    • 1
  • Suresh Hedau
    • 1
  • Ajay Singh
    • 2
  • Premasis Kar
    • 2
  • Bhudev C. Das
    • 1
  1. 1.Division of Molecular OncologyInstitute of Cytology and Preventive Oncology (ICMR)NoidaIndia
  2. 2.Department of MedicineLok Nayak HospitalNew DelhiIndia

Personalised recommendations